Progress Update on STING Agonists as Vaccine Adjuvants
Vaccines · 31.03.2025 · 13 (4) · 371
DOI: 10.3390/vaccines13040371 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 31.03.2025. Verfasst von Yanru Shen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIF…. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China.
Abstract (Originalsprache)
Low antigen immunogenicity poses a significant challenge in vaccine development, often leading to inadequate immune responses and reduced vaccine efficacy. Therefore, the discovery of potent immune-enhancing adjuvants is crucial. STING (stimulator of interferon genes) agonists are a promising class of adjuvants which have been identified in various immune cells and are activated in response to DNA fragments, triggering a broad range of type-I interferon-dependent immune responses. Integrating STING agonists with vaccine components is an ideal strategy to bolster vaccine-induced immunity to infections and cancer cells. Several STING agonists are currently under investigation in preclinical studies and clinical trials; however, some have shown limited efficacy, while others exhibit off-target effects. To ensure safety, they are typically delivered with carriers that exhibit high biocompatibility and insolubility. In this review, we present the latest research on natural and synthetic STING agonists that have been effectively used in vaccine development, and summarize their application in adjuvant preventive and therapeutic vaccines. Additionally, we discuss the safety of STING agonists as vaccine adjuvants by reviewing potential delivery strategies. Overall, incorporating STING agonists into vaccine formulations represents a significant advancement in vaccine research with the potential to significantly enhance immune responses and improve vaccine efficacy. However, ongoing research is still required to identify the most effective and safe delivery strategies for STING agonists, as well as to evaluate their long-term safety and efficacy in clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
- WHO Collaborating Center for Standardization and Evaluation of Biologicals, Beijing 102629, China.
- NHC Key Laboratory of Research on Quality and Standardization of Biotech Products and NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102629, China.
ORCID-Profile: Weijin Huang, Jianhui Nie, Li Zhang
Förderung
- National Key Research and Development Program of China
Zitieren
APA
Shen, Y., Huang, W., Nie, J., & Zhang, L. (2025). Progress Update on STING Agonists as Vaccine Adjuvants. Vaccines, 13(4), 371. https://doi.org/10.3390/vaccines13040371
Vancouver
Shen Y, Huang W, Nie J, Zhang L. Progress Update on STING Agonists as Vaccine Adjuvants. Vaccines. 2025;13(4):371. doi:10.3390/vaccines13040371
BibTeX
@article{Shen2025,
author = {Shen, Yanru and Huang, Weijin and Nie, Jianhui and Zhang, Li},
title = {Progress Update on STING Agonists as Vaccine Adjuvants},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {4},
pages = {371},
doi = {10.3390/vaccines13040371}
}
EUVIMED